Optinose
-
After Fielding Multiple Offers, Yardley-Based Optinose Secures Potential $330M Deal With Paratek
Yardley-based Optinose, which put itself up for auction three years ago attracting multiple suitors, has secured a potential $330 million deal with Paratek, writes John…
-
Paratek Pharmaceuticals Acquires Yardley-Based Optinose in $330M Deal
Paratek Pharmaceuticals of Boston has entered into a definitive agreement to buy Yardley-based Optinose in a deal worth up to $330 million, writes John George…
-
Yardley-Based Optinose Implements Reverse Stock Split to Boost Share Price, Avoid NASDAQ Delisting
Yardley-based Optinose will enact a 1-for-15 reverse stock split to boost its share price and fend off a potential NASDAQ delisting, writes Ryan Mulligan for…
-
Yardley-Based Optinose’s Xhance Nasal Spray Wins FDA Nod for Chronic Rhinosinusitis
Yardley-based Optinose got the green light from the Food and Drug Administration for their flagship nasal spray Xhance, writes John George for the Philadelphia Business…
-
Optinose Awaits FDA Verdict on Expansion for Chronic Rhinosinusitis Treatment
Yardley-based Optinose, known for its drug-device product Xhance, is at a pivotal moment as it awaits a decision from the Food and Drug Administration, writes…
-
Several Public Companies in Bucks County Listed Among Largest in Philadelphia Region
Several businesses in Bucks County were recently listed among the top public companies in the local region. Todd Romero wrote about the companies for the…
-
CEO of Yardley Pharmaceutical Company Retires After 13 Years, Company’s President to Take Over
As the longtime CEO of a major Bucks County company announces his retirement, his replacement has already been chosen and announced. John George wrote about…
-
Yardley Pharmaceutical Company Expects to Raise $50M From Public Stock Offering
A Bucks County pharmaceutical company is set to raise a large sum of money through recent financial dealings they have partaken in. John George wrote…
-
Yardley Chief Financial Officer Noses His Career in a New Direction
Optinose, the Yardley pharmaceutical company, has announced that Chief Financial Officer Keith A. Goldan has accepted a position at another public company. Optinose focuses on…
-
Optinose, Yardley, Looks to Raise $40M — Nothing to Sneeze at — to Expand Nasal Drug Delivery Device Line
Late last week, Optinose of Yardley closed its effort to raise $40 million through the sale of company stock. The capital infusion will expand its…
Founding Partners
Advertisement
Affiliate Partners
